US EditionRevalesio to Present Phase 3 Trial Design and Post Hoc Analysis of Phase 2 RESCUE Trial of RNS60 in Acute Ischemic Stroke at the SNIS 22nd Annual Meeting
Summary by Eastern Progress
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Revalesio to Present Phase 3 Trial Design and Post Hoc Analysis of Phase 2 RESCUE Trial of RNS60 in Acute Ischemic Stroke at the SNIS 22nd Annual Meeting
TACOMA, Wash., July 14, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that two abstracts featuring its investigational treatment RNS60 in acute ischemic stroke have been accepted for oral presentation…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
